President Trump unveiled plans Tuesday for a new website that will allow Americans to buy prescription drugs directly from their manufacturers — potentially lowering out-of-pocket costs, though details remain murky.
Trump, 79, announced the planned “TrumpRx” website, due to launch in early 2026, alongside Pfizer CEO Albert Bourla in the Oval Office.
Pfizer partnered on the initiative as part of a broader deal with the Trump administration to lower the rate that the federal government pays for drugs through Medicare. President Trump announced the launch of the "TrumpRx" website in the Oval Office on Sept. 30, 2025.
Many aspects of the ambitious plan intended to equalize drug costs between the US and other major Western countries remain unclear.
It’s also not certain what benefits, if any, would flow to customers with private insurance, who comprise about two-thirds of the US population.
“I think it’s one of the biggest things that we’ll do. We’ll be reducing drug prices by 100% in some cases, 300% or more,” Trump told reporters on the South Lawn of the White House ahead of the announcement.
“Pfizer is committing to offer all of their prescription medications to Medicaid, and it will be at the most favored nation prices,” the president said moments later in the Oval Office. “It’s going to have a huge impact on bringing Medicaid costs down, like nothing else.”
Most favored nation (MFN) prices are calculated by taking US consumer prices and comparing them against eight other wealthy countries (Canada, United Kingdom, France, Germany, Italy, Japan, Denmark and Switzerland).
The final price then gets negotiated with the US market in mind, in theory resulting in a near-perfect equalization of the price Americans and foreigners pay.
For the TrumpRx website, Pfizer agreed to provide some of their popular medications at discounted rates of between 50 and 100%, and all new medications announced will be offered in the US at the most favored nation rate, Trump said.
Medications that will available on TrumpRx include Xeljanz for rheumatoid arthritis (40% discount), Zavzpret for migraines (50%), Eucrisa for dermatitis (80%), and Duavee for female osteoporosis (85%). --->READ MORE HERE
 |
| Win McNamee/Getty Images |
Pfizer has agreed to lower the cost of prescription drugs for Medicaid under a deal struck with the Trump administration, President Donald Trump said Tuesday as he promised similar deals with other drugmakers under the threat of tariffs.
Trump made the announcement at the White House alongside Pfizer CEO Albert Bourla just hours ahead of a possible government shutdown in a partisan standoff over health care and spending.
Pfizer Inc., one of the largest U.S. drugmakers, produces the COVID-19 vaccine Comirnaty and the treatment Paxlovid. Its products also include several cancer drugs, the blood thinner Eliquis and the pneumonia vaccine Prevnar.
Under the deal, New York-based Pfizer will charge most-favored-nation pricing to Medicaid and guarantee that pricing on newly launched drugs, Trump said. That involves matching the lowest price offered in other developed nations.
The agreement by Pfizfer builds on an executive order Trump signed in May setting a deadline for drugmakers to electively lower prices or face new limits on what the government will pay. Trump said deals with other drug companies would be coming over the next week.
“I can’t tell you how big this is,” the president said Tuesday.
“We are turning the tide and we are reversing an unfair situation,” Bourla said.
Consumers are not expected to start seeing lower prices under the Pfizer deal until 2026, according to senior administration officials who were not authorized to speak publicly and spoke on condition of anonymity. --->READ MORE HEREFollow links below to relevant/related stories and resources:
Study finds COVID-19 damage to sense of smell can last years
Chronic truancy at Louisiana schools has been elevated since COVID-19
USA TODAY: Coronavirus Updates
WSJ: Coronavirus Live Updates
YAHOO NEWS: Coronavirus Live Updates
NEW YORK POST: Coronavirus The Latest
If you like what you see, please "Like" and/or Follow us on FACEBOOK here, GETTR here, and TWITTER here.
No comments:
Post a Comment